Epidermal growth factor receptor inhibitor (EGFRI) -related paronychia is a condition clearly related to EGFRI therapy, characterized by periungual erythema, edema, purulent exudates, periungual or subungual granulomatous lesions, and sometimes accompanied by thinning, fragility or even splitting and seperation of nail plates. Inhibition of epidermal function, inflammation and secondary infections, as well as angiogenesis are the core processes in the occurrence and development of EGFRI-related paronychia. This review summarizes epidemiology, pathogenesis, clinical manifestations, prevention and treatment of EGFRI-related paronychia.

Epidermal growth factor receptor inhibitor (EGFRI) -related paronychia is a condition clearly related to EGFRI therapy, characterized by periungual erythema, edema, purulent exudates, periungual or subungual granulomatous lesions, and sometimes accompanied by thinning, fragility or even splitting and seperation of nail plates. Inhibition of epidermal function, inflammation and secondary infections, as well as angiogenesis are the core processes in the occurrence and development of EGFRI-related paronychia. This review summarizes epidemiology, pathogenesis, clinical manifestations, prevention and treatment of EGFRI-related paronychia.

Polyurethane (PUR) plastics is widely used because of its unique physical and chemical properties. However, unreasonable disposal of the vast amount of used PUR plastics has caused serious environmental pollution. The efficient degradation and utilization of used PUR plastics by means of microorganisms has become one of the current research hotspots, and efficient PUR degrading microbes are the key to the biological treatment of PUR plastics. In this study, an Impranil DLN-degrading bacteria G-11 was isolated from used PUR plastic samples collected from landfill, and its PUR-degrading characteristics were studied. Strain G-11 was identified as Amycolatopsis sp. through 16S rRNA gene sequence alignment. PUR degradation experiment showed that the weight loss rate of the commercial PUR plastics upon treatment of strain G-11 was 4.67%. Scanning electron microscope (SEM) showed that the surface structure of G-11-treated PUR plastics was destroyed with an eroded morphology. Contact angle and thermogravimetry analysis (TGA) showed that the hydrophilicity of PUR plastics increased along with decreased thermal stability upon treatment by strain G-11, which were consistent with the weight loss and morphological observation. These results indicated that strain G-11 isolated from landfill has potential application in biodegradation of waste PUR plastics.
Plastics/metabolism* ; Polyurethanes/chemistry* ; RNA, Ribosomal, 16S ; Bacteria/genetics* ; Biodegradation, Environmental

Irinotecan is an anticancer topoisomerase I inhibitor that acts as a prodrug of the active metabolite, SN-38. Unfortunately, the limited utility of irinotecan is attributed to its pH-dependent stability, short half-life and dose-limiting toxicity. To address this problem, a novel trivalent PEGylated prodrug (PEG-[Irinotecan]₃) has been synthesized and its full-profile pharmacokinetics, antitumor activity and toxicity compared with those of irinotecan. The results show that after intravenous administration to rats, PEG-[Irinotecan]₃ undergoes stepwise loss of irinotecan to form PEG-[Irinotecan]_3‒x (x = 1,2) and PEG-[linker] during which time the released irinotecan undergoes conversion to SN-38. As compared with conventional irinotecan, PEG-[Irinotecan]₃ displays extended release of irinotecan and efficient formation of SN-38 with significantly improved AUC and half-life. In a colorectal cancer-bearing model in nude mice, the tumor concentrations of irinotecan and SN-38 produced by PEG-[Irinotecan]₃ were respectively 86.2 and 2293 times higher at 48 h than produced by irinotecan. In summary, PEG-[Irinotecan]₃ displays superior pharmacokinetic characteristics and antitumor activity with lower toxicity than irinotecan. This supports the view that PEG-[Irinotecan]₃ is a superior anticancer drug to irinotecan and it has entered the phase II trial stage.

Objective:To investigate the safety and efficacy of anlotinib in treatment of advanced malignant tumors.Methods:The clinical data of 65 patients with advanced malignant tumors after the failure of the second-line treatment in Shanxi Bethune Hospital from July 2018 to July 2019 were retrospectively analyzed, including 32 cases of non-small cell lung cancer, 12 cases of small cell lung cancer, 15 cases of ovarian cancer, and 6 cases of peritoneal cancer. The objective total remission rate (ORR), disease control rate (DCR), progression-free survival (PFS) time, and the related adverse events were also analyzed.Results:ORR in non-small cell lung cancer group was 43.7% (14/32), DCR was 68.8% (22/32); ORR in small cell lung cancer group was 8.3% (1/12), and DCR was 25.0% (3/12). ORR in ovarian cancer group was 33.3% (5/15), DCR was 73.3% (11/15). In peritoneal carcinoma group, ORR was 0 (0/6) and DCR was 33.3% (2/6). The median PFS time was 8.0 months (95% CI 6.2-9.8 months) in the non-small cell lung cancer group, 3.0 months (95% CI 1.9-4.1 months) in the small cell lung cancer group, 5.0 months (95% CI 3.1-6.9 months) in the ovarian cancer group, and 2.0 months (95% CI 0.0-5.6 months) in the peritoneal cancer group. Hypertension was the most common non-hematology-related adverse event, and there were 6 cases (9.2%) of grade Ⅰ-Ⅱ adverse event and 1 case (1.5%) of grade Ⅲ-Ⅳ adverse event. Among the hematology-related adverse events, thrombocytopenia was the most common, and there were 8 cases (12.3%) of grade Ⅰ-Ⅱ adverse event and 1 case (1.5%) of grade Ⅲ-Ⅳ adverse event. All patients could tolerate the adverse reactions. Conclusion:Anlotinib is one of the options for the treatment of advanced malignant tumors, with mild drug-related adverse reactions and definite efficacy.

Objective To investigate the safety and efficacy of low-dose apatinib in treatment of advanced malignant tumors. Methods The clinical data of 54 patients with advanced malignant tumors who were admitted to Shanxi Dayi Hospital from March 2015 to March 2018 were analyzed retrospectively. These patients were treated with apatinib at doses of 250 mg (29 cases) and 500 mg (25 cases) after initial treatment or failure of multi-line treatment. There were 15 cases of gastric cancer, 11 cases of lung cancer, 9 cases of ovarian cancer, 7 cases of liver cancer, 6 cases of soft tissue sarcoma, 3 cases of esophageal cancer, 2 cases of melanoma, and 1 case of peritoneal cancer. The objective response rate (ORR), disease control rate (DCR), progress free survival (PFS) and overall survival (OS) were analyzed, and the efficacy and related adverse reactions were evaluated. Results The adverse reactions of 54 patients could be evaluated. Non-hematological drug-related adverse reactions were most common with hypertension, hand-foot skin reaction and proteinuria, while hematologic drug-related adverse reactions were most common with leukopenia and thrombocytopenia. All patients were well tolerated. The incidence of drug-related adverse reactions in the 250 mg dose group was lower than that in the 500 mg dose group, and the incidence of grade Ⅰ-Ⅱhypertension between the two groups was statistically different (χ2 = 6.268, P= 0.012). Short-term efficacy:ORR of the patients in the 250 mg and 500 mg dose groups was 6.9％ (2/29) and 12.0％ (3/25), respectively;DCR was 41.4％ (12/29) and 52.0％ (13/25), respectively; and the 500 mg dose group was superior to the250 mg dose group, but the differences were not statistically significant (ORR: χ2= 0.416, P= 0.519; DCR:χ2= 0.609, P= 0.435). Long-term efficacy: the 500 mg dose group had a slight advantage over the 250 mg dose group in both median PFS time (3.9 months vs. 3.6 months) and median OS time (7.8 months vs. 7.6 months), but the differences were not statistically significant (PFS:χ2=0.472, P=0.492; OS:χ2=0.261, P=0.609). Conclusions Low-dose apatinib can be used to treat advanced malignant tumors. The drug-related adverse reactions are small, the curative effects are exact, the adverse reactions are easy to tolerate, and it is convenient for long-term use. Low-dose apatinib is one of the treatment options for advanced malignant tumors.

［ ［Abstract］ ］Objective: To analyze and compare the clinical efficacy and safety of dendritic cell cytokine-induced killer cells (DCCIK) combined with palliative therapy or chemotherapy in the treatment of advanced pancreatic carcinoma. Methods: A retrospective study was carried on 50 patients with advanced pancreatic carcinoma who were hospitalized in department of oncology of Shanxi Dayi Hospital during September 2012 to February 2016. The patients were divided into four groups according to the therapy they received (palliative treatment group, palliative+DC-CIK treatment group, chemotherapy group and chemotherapy+DC-CIK treatment group); the immunological function, quality of life and survival time of patients were analyzed; and the efficacy and safety of DC-CIK cell therapy was also evaluated. Results: The percentages of CD8+ T cells and NKT cells in DC-CIK combined therapy groups were significantly improved compared with that of pre-treatment, and the percentages of CD3+, CD8+, NK, NKT cells were increased compared with control groups (P<0.05). The quality of life of patients was significantly improved (P<0.05), while median PFS and median OS were improved but without statistical significance (P>0.05). Conclusion: Compared with palliative therapy and chemotherapy alone, combined DC-CIK immunotherapy can effectively improve the cellular immunity function and quality of life in patients with advanced pancreatic cancer. However, there was no significant extension in overall survival.

Objective To explore the influencing factors of fear of progression among postoperative elderly patients with prostatic cancer. Methods From December 2016 to December 2017, we selected 404 elderly prostatic cancer patients with surgical treatment of Urinary Surgery in Tangshan People's Hospital as subjects by purposive sampling. All of the patients were investigated with the Fear of Progression Questionnaire-Short Form (FoPQ-SF), Readiness for Hospital Discharge (RHD), the Chinese Version of the M. D. Anderson Symptom Inventory and Family Adaptability and Cohesion Scale Ⅱ (FACES Ⅱ). Binary Logistic regression was used to analyze the influencing factors of fear of progression among postoperative elderly patients with prostatic cancer. Results The total of 404 elderly prostatic cancer patients were divided into two groups according to FoPQ-SF, 202 patients with the score of FoPQ-SF less than or equal to 34 in control group and 202 patients with the score of FoPQ-SF more than 34 in case group. There were statistical differences in ages, family support, clinical stages, scores of Gleason, symptom distress and readiness for hospital discharge of patients between two groups (χ2=10.164, 24.762, 21.083, 21.052, 21.915, 25.783;P＜ 0.05). Logistic regression analysis showed that the influencing factors of fear of progression among postoperative elderly patients with prostatic cancer included ages, family support, readiness for hospital discharge, symptom distress and scores of Gleason (P＜ 0.05). Conclusions Fear of progression among postoperative elderly patients with prostatic cancer is affected by many factors. Improving patients' readiness for hospital discharge will help to lower the fear of progression of patients.

Objective To detect the changes of 25-hydroxy vitamin D (25-OH-D) and blood calcium concentrations in the serum of prostate cancer (Pca) patients with bone metastases,and to analyze the correlation between bone calcium metabolism and bone metastasis of prostate cancer.Methods The 35 untreated prostate cancer patients without bone metastases,30 patients with bone metastasis of prostate cancer,and 30 healthy controls were selected,and fluorescent immune chromatography was used to determine the content of 25-OH-D,the Azo arsenic method was used to detect the blood calcium level,and ROC curve was used to analyze the value of two indexes in diagnosing prostate cancer bone metastases.Results The blood calcium content in bone metastasis of prostate cancer group was significantly higher than the other groups (P ＜ 0.05),and the prostate cancer group had a higher blood calcium content than healthy controls (P ＜ 0.05).For 25-OH-D content,bone metastases of prostate cancer group was significantly lower than the other groups (P ＜0.05).25-OH-D level showed a negative correlation with blood calcium in each group (r =0.628,P ＜ 0.05).The ROC curve showed levels of blood calcium and 25-OH-D in the diagnosis of bone metastases of prostate cancer were 0.763 and 0.712.Conclusion The high blood calcium and low vitamin D levels may be an effective predictor for bone metastases of prostate cancer.

Objective To detect the changes of 25-hydroxy vitamin D (25-OH-D) and blood calcium concentrations in the serum of prostate cancer (Pca) patients with bone metastases,and to analyze the correlation between bone calcium metabolism and bone metastasis of prostate cancer.Methods The 35 untreated prostate cancer patients without bone metastases,30 patients with bone metastasis of prostate cancer,and 30 healthy controls were selected,and fluorescent immune chromatography was used to determine the content of 25-OH-D,the Azo arsenic method was used to detect the blood calcium level,and ROC curve was used to analyze the value of two indexes in diagnosing prostate cancer bone metastases.Results The blood calcium content in bone metastasis of prostate cancer group was significantly higher than the other groups (P ＜ 0.05),and the prostate cancer group had a higher blood calcium content than healthy controls (P ＜ 0.05).For 25-OH-D content,bone metastases of prostate cancer group was significantly lower than the other groups (P ＜0.05).25-OH-D level showed a negative correlation with blood calcium in each group (r =0.628,P ＜ 0.05).The ROC curve showed levels of blood calcium and 25-OH-D in the diagnosis of bone metastases of prostate cancer were 0.763 and 0.712.Conclusion The high blood calcium and low vitamin D levels may be an effective predictor for bone metastases of prostate cancer.